Sugi Predict

Sugi Predict / Compounds / SCHEMBL2041007

SCHEMBL2041007

SCHEMBL2041007

O=C(O)c1ccc(-c2ccccc2)c(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 1/20 0.56
▸ ADH5 P11766 1/20 0.55
▸ PTGS1 P23219 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ PTGS2 P35354 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ AKR1C3 P42330 2/20 0.54
▸ AKR1C2 P52895 2/20 0.54
▸ FABP2 P12104 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ AKR1C4 P17516 1/20 0.54
▸ ADRA2B P18089 1/20 0.54
▸ CHRM3 P20309 1/20 0.54
▸ HTR2C P28335 1/20 0.54
▸ DRD3 P35462 1/20 0.54
▸ AKR1C1 Q04828 1/20 0.54
▸ SLC22A6 Q4U2R8 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29473809 1.00 RARB (0.56) RARBADH5PTGS1MEN1PTGS2
SCHEMBL6252810 0.90 RARB (0.61) RARBADH5MEN1KMT2AAKR1C3
SCHEMBL26572449 0.87 BCL2L1 (0.62) RARBADH5MEN1PTGS2KMT2A
SCHEMBL505879 0.86 AKR1C3 (0.56) RARBADH5MEN1KMT2AAKR1C3
SCHEMBL14213193 0.86 LMNA (0.57) RARBADH5PTGS2KMT2AAKR1C3
SCHEMBL24959781 0.85 PTGS1 (0.51) RARBADH5PTGS1MEN1PTGS2
SCHEMBL10269902 0.85 PTGS1 (0.55) RARBPTGS1MEN1PTGS2KMT2A
SCHEMBL28218967 0.85 PTGS1 (0.51) PTGS1MEN1PTGS2KMT2AAKR1C3
SCHEMBL16104362 0.85 PTGS1 (0.51) RARBADH5PTGS1MEN1PTGS2
SCHEMBL5728663 0.85 TTR (0.56) RARBKMT2ALMNACYP2C9AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118191177-B Method for separating and determining impurities in flurbiprofen axetil injection by using HPLC-based correction factor method 山东省食品药品检验研究院 2024-11-12 — — CN claimed
CN-118191177-A Method for separating and determining impurities in flurbiprofen axetil injection by using HPLC-based correction factor method 山东省食品药品检验研究院 2024-06-14 — — CN claimed
CN-117832755-A Functional diaphragm for lithium-sulfur battery and preparation method thereof 成都职业技术学院 2024-04-05 — — CN claimed
US-9429663-B2 Compounds for neutron radiation detectors and systems thereof LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2016-08-30 — — US claimed
US-8872125-B2 Solution-grown crystals for neutron radiation detectors, and methods of solution growth LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2014-10-28 — — US claimed
US-20140291532-A1 COMPOUNDS FOR NEUTRON RADIATION DETECTORS AND SYSTEMS THEREOF LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2014-10-02 — — US claimed
US-8835865-B2 Mixed crystal organic scintillators LAWRENCE LIVERMORE NATIONAL SECURITY, LLC. (US) 2014-09-16 — — US claimed
US-8735843-B2 Compounds for neutron radiation detectors and systems thereof LAWRENCE LIVERMORE NATIONAL SECURITY, LLC. (US) 2014-05-27 — — US claimed
US-20140124677-A1 MIXED CRYSTAL ORGANIC SCINTILLATORS LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2014-05-08 — — US claimed
US-20130181135-A1 COMPOUNDS FOR NEUTRON RADIATION DETECTORS AND SYSTEMS THEREOF LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2013-07-18 — — US claimed
US-20100252741-A1 SOLUTION-GROWN CRYSTALS FOR NEUTRON RADIATION DETECTORS, AND METHODS OF SOLUTION GROWTH U.S. DEPARTMENT OF ENERGY 2010-10-07 — — US claimed
US-20100125139-A1 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF BANKSTON DONALD 2010-05-20 — — US claimed
EP-1667958-A2 MELANIN CONCENTRATING HORMONE ANTAGONISTS THE PROCTER & GAMBLE COMPANY (US) 2006-06-14 — — EP claimed
EP-1370553-B1 RHO-KINASE INHIBITORS BAYER AG (US) 2006-05-10 — — EP claimed
EP-1542992-A2 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF Bayer Corporation (US) 2005-06-22 — — EP claimed
WO-2005033063-A2 MELANIN CONCENTRATING HORMONE ANTAGONISTS THE PROCTER & GAMBLE COMPANY (US) 2005-04-14 — — WO claimed
WO-2004029045-A2 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF BAYER PHARMACEUTICALS CORPORATION (US) 2004-04-08 — — WO claimed
EP-1370553-A2 RHO-KINASE INHIBITORS Bayer Corporation (US) 2003-12-17 — — EP claimed
US-20030220357-A1 Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof BAYER HEALTHCARE LLC 2003-11-27 — — US claimed
WO-2002076976-A2 RHO-KINASE INHIBITORS BAYER CORPORATION (US) 2002-10-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220357-A1 Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof ROCK1, ROCK2, RHOT2 RARB 3190/4885ADH5 2291/4885PTGS1 308/4885
US-20100125139-A1 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF ROCK1, ROCK2, CIT RARB 2707/4885ADH5 2562/4885PTGS1 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.